3-Hydroxy Midostaurin [also known as CGP-52421; CGP52421] is a metabolite of midostaurin (PKC-412), which is a multiple kinase inhibitor and an anticancer drug approved in 2017 by FDA to treat acute myeloid leukemia. 3-Hydroxy Midostaurin acts as an inhibitor of FMS-like tyrosine kinase-3 (FLT3).

纯度：≥98%

CAS：120685-11-2